鹏华国证疫苗与生物科技ETF(159657)利润分配表
| |
2024-12-31 |
2024-06-30 |
2023-12-31 |
2023-06-30 |
| 收入 |
-50,123,821.60 |
-59,982,792.09 |
-66,797,637.31 |
-75,060,267.41 |
| 利息合计 |
66,290.56 |
50,730.38 |
590,670.36 |
519,044.07 |
| 其中：存款利息收入 |
31,936.51 |
16,376.33 |
565,898.73 |
519,044.07 |
| 债券利息收入 |
- |
- |
- |
- |
| 资产支持证券利息收入 |
- |
- |
- |
- |
| 买入返售金融资产收入 |
787.33 |
787.33 |
- |
- |
| 投资收益合计 |
-23,297,934.04 |
-8,810,928.34 |
-33,318,534.19 |
-13,138,939.77 |
| 其中：股票投资收益 |
-25,787,801.04 |
-10,117,616.75 |
-36,507,530.19 |
-15,265,512.61 |
| 基金投资收益 |
- |
- |
- |
- |
| 债券投资收益 |
- |
- |
- |
- |
| 资产支持证券投资收益 |
- |
- |
- |
- |
| 衍生工具收益 |
- |
- |
- |
- |
| 股利收益 |
2,489,867.00 |
1,306,688.41 |
3,188,996.00 |
2,126,572.84 |
| 基金分红收益收益 |
- |
- |
- |
- |
| 公允价值变动收益 |
-26,911,190.00 |
-51,204,089.64 |
-33,915,057.51 |
-62,240,354.70 |
| 其他收入 |
19,011.88 |
-18,504.49 |
-154,715.97 |
-200,017.01 |
| 费用 |
1,207,432.19 |
661,966.50 |
1,873,037.00 |
1,018,987.45 |
| 管理人报酬 |
743,592.72 |
412,304.24 |
1,394,115.27 |
769,648.79 |
| 基金托管费 |
148,718.57 |
82,460.88 |
278,823.00 |
153,929.77 |
| 销售服务费 |
- |
- |
- |
- |
| 交易费用 |
- |
- |
- |
- |
| 利息支出 |
- |
- |
- |
- |
| 其中：卖出回购金融资产支出 |
- |
- |
- |
- |
| 其他费用 |
315,000.00 |
167,080.48 |
200,009.59 |
95,408.89 |
| 利润总额 |
-51,331,253.79 |
-60,644,758.59 |
-68,670,674.31 |
-76,079,254.86 |
微信公众号
证券之星APP
基本资料
